March-In Rights Alone Won’t Solve Our Drug Pricing Problems

By Rachel Sachs

On Monday, a group of over 50 members of Congress sent a letter urging the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) to use a little-known statutory provision to take action against high drug prices.  Their goal is laudable, and HHS and the NIH should certainly offer guidance in this area – but the existing law offers only a partial solution to the problem as the legislators describe it.

The members of Congress wrote to remind HHS and the NIH of a provision in the 1980 Bayh-Dole Act giving the government “march-in rights” to patents resulting from government-funded research.  More specifically, the statute spells out a range of conditions under which the government may require a patentholder to grant licenses on reasonable terms to others to practice the patent.  The government may require such a license where “action is necessary to alleviate health or safety needs which are not reasonably satisfied,” 35 U.S.C. § 203(a)(2), or where the benefits of the invention are not being made “available to the public on reasonable terms,” 35 U.S.C. § 201(f).  The legislators argue that many drugs today violate these conditions, as even many insured Americans cannot access prescription drugs without incurring significant financial harm.

Although the “march-in rights” provision has existed in the statute since 1980, it has never been exercised by the federal government, even when it has been specifically asked.  And some of these cases have been paradigmatic examples where “health or safety needs” are not being satisfied.  A December 2015 study notes that in Bayh-Dole’s history, there have only been five petitions requesting that the NIH exercise its march-in rights.  Three of those requests were based on high prices for drugs for HIV/AIDS and glaucoma, and one was based on a persistent drug shortage which may have caused the deaths of people with Fabry disease, a rare condition.  (The fifth petition involved a medical device under patent litigation at the time.)  The NIH denied each request.  Some scholars argued that if the NIH denied the Fabry disease petition, where Genzyme’s drug shortages lasted for multiple years and caused great suffering, possibly including death, there may be no circumstances under which the NIH would grant such a petition.

The legislators here urge HHS and the NIH to issue “official guidance regarding the situations in which march-in rights would apply,” suggesting that “reasonable guidelines can discourage drug price gouging.”  Such official guidance should absolutely be issued – but I’m skeptical that it will materially address the drug price issue.  Although there are many reasons why, in the interest of space I will explain only three here briefly.

  1. Multiple Patents. Unfortunately, there is not usually a one-to-one correspondence between a drug and a patent. As scholars have noted, most small-molecule drugs are protected by several patents, with an average of 3.5 patents per drug as of 2005.  Some drugs are protected by 10 or more patents.  Where some but not all of a drug’s patents were developed under a funding agreement with the federal government, a license to practice a subset of a drug’s patents is likely not be the same as a license to the drug itself.  This may be a legal question that would need to be answered during the lengthy appeals process the law provides the entities affected by a march-in determination, during which the march-in would be on hold, under 35 U.S.C. § 203(b).
  1. The FDA. The legislators’ letter focuses on the NIH, as the primary funding agency for the basic research that leads to the discovery of many new drugs. And the march-in rights provision does give the NIH the ability to grant another company the right to make and use the particular technology without fear of infringement liability.  But here’s the problem: where the technology at issue is a drug, licensing the technology to another company isn’t sufficient to create improved access to that drug.  The competitor has to get its drug approved by the FDA.  And if the drug in question has only recently entered the market, there may be an FDA exclusivity period (typically lasting either five, seven, or twelve years, depending on the drug) preventing the FDA from granting approval or preventing the new licensee from relying on the originator drug’s clinical trials to get on the market.  A licensee who has to conduct their own clinical trials won’t make it to market for many years, and the expenses incurred in that process would raise the price of the competitor’s drug.
  1. The Denominator Problem. Many (perhaps most) drugs are developed on the basis of basic research funded by the federal government. But fewer drugs are directly covered by patents developed on the basis of federal funding.  (Note: where a drug isn’t covered by such a patent but nonetheless is derived from one, we may have a separate legal problem defining the “subject invention.”)  March-in rights thus won’t reach all patented drugs.  March-in rights will also not reach high-priced off-patent drugs, as Martin Shkreli most notably brought to the public’s attention.  The subset of drugs these legislators are concerned about is not the same as the subset of drugs reachable through the Bayh-Dole Act.

I don’t present these concerns to suggest that march-in rights are irrelevant, or to suggest that high drug prices (particularly high out-of-pocket costs for patients) aren’t having a harmful effect on our health care system.  But I do want to suggest that the very people writing this letter – members of Congress – have the power to pass laws fixing at least some, if not all, of the other problems I identify above.  This is not a problem solely for the executive branch.  I do hope the NIH and HHS release guidance on march-in rights, but they need Congress’ help to make real change.

This entry was posted in FDA, Health Law Policy, Intellectual Property, Pharmaceuticals, Rachel Sachs, Research Funding by rachelsachs. Bookmark the permalink.

About rachelsachs

Rachel Sachs is an Associate Professor at the Washington University in St. Louis School of Law. Previously, she was an Academic Fellow at the Petrie-Flom Center. Rachel earned her J.D. in 2013 magna cum laude from Harvard Law School, where she was the Articles Chair of the Harvard Law Review and a student fellow with both the Petrie-Flom Center and the John M. Olin Center for Law, Economics, and Business. Rachel has also earned a Master of Public Health from the Harvard School of Public Health, during which she interned at the United States Department of Health and Human Services. Rachel's primary research interests lie at the intersection of patent law and health law, with a particular focus on problems of innovation and access and the ways in which law helps or hinders these problems.

2 thoughts on “March-In Rights Alone Won’t Solve Our Drug Pricing Problems

  1. The members of Congress sent a letter urging the existing statutory authority to respond to the soaring cost of pharmaceuticals; and urged NIH to issue guides to effect this goal. The expensive drug prices are not for kind of disease. The affordable drugs are appreciated by low-income people. The pharmaceutical companies manufacture drugs for health care; and the affordability is imperative and cannot be impotent for the low in-come people. The Obamacare is that health plan offered by private health companies.

  2. As someone who has been involved in more NIH March-In cases than anyone else, I agree with the author that the March-In remedies are limited, for the reasons that she mentions. However, when the remedy is appropriate, it should be used, and I think she agrees with that. Today we filed a petition for the federal government to use its royalty free rights or the march-in remedy for all three of the Orange Book patents on Xtandi, a $129k per year prostate cancer drug invented at UCLA on NiH and DoD grants, grants that are reported on each of the patents. The FDA test data monopolies expire in 2017. The drug is a relatively easy to manufacturer small molecule. Astellas, the Japanese company that sells Xtandi, charges U.S. residents more than 3 times the price in Japan, more than 4 times the price in Canada, and 2.5 time more than the price anywhere else in the world. The cumulative sales will soon exceed more than $5 billion, most from the US market and Medicare in particular, and the R&D outlays associated with its 2012 approval, were fairly modest, and mostly in the lower risk Phase III trial used in its fast track approval. If the NIH does not do something in this case, the Obama Administration really has no appetite for dealing with high drug prices. If the Administration does engage in the petition, it can at least learn how to say no to high prices, and build on that exercise later, and save U.S. residents a few billion along the way. Sometimes a journey begins with a single step. http://www.keionline.org/node/2412

Comments are closed.